---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115334"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:13:19.651239+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel Q3 net income $12.4M vs year-ago loss; revenue $55.3M, led by TAVALISSE +8%

## Summary
- Total Q3 revenue $55.3M; net income $12.4M ($0.71 basic EPS) vs net loss $5.7M in Q3 2023.
- TAVALISSE net sales $26.3M (+8% YoY); REZLIDHIA $5.5M (+107% YoY); GAVRETO $7.1M (first full quarter).
- Received $10M upfront from Kissei license for REZLIDHIA in Japan, Korea, Taiwan; up to $152.5M milestones.
- R289 Phase 1b in LR-MDS: RBC-TI/hematologic improvement in 36% at doses ≥500 mg QD; median duration 29 weeks.
- Cash and investments $61.1M at Sep 30, up from $49.1M at Jun 30 and $56.9M at Dec 31, 2023.

## SEC filing metadata
- accession: 0001104659-24-115334
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465924115334/0001104659-24-115334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465924115334/tm2427717d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115334
- JSON: https://secwatch.observer/filing/0001104659-24-115334.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.